England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics
Executive Summary
Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.
You may also be interested in...
Results Imminent From Sweden’s Pilot Of Novel Antibiotic Reimbursement Model
If successful, a new Swedish model for reimbursing antibiotics that involves guaranteed minimum annual revenues for companies, could be tested on other kinds of products.
GSK Hails Success For Novel Antibiotic – But Reaching $1bn Sales Will Be A Challenge
GSK is returning to its long heritage in antibiotics with a potential first-in-class drug that has just shown promise in urinary tract infection; hopes are that it can reach annual sales of $1bn.
Transferable Exclusivity Extension Vouchers Are Viable In Europe, But Back Up Required
A new study shows that transferable exclusivity extension vouchers are the best way of incentivizing antibiotic development in Europe. However, investors caution that other strategies must also be considered.